MTNB: Matinas BioPharma Holdings, Inc. Company Short-Term Debt

Symbol and logo of brand Matinas BioPharma Holdings Inc. (MTNB)

Matinas BioPharma (MTNB) is creating a defensive asset through a proprietary drug delivery system into cells, which guarantees stable demand. The implementation of digital assistants and automated molecule analysis stations, reflected in the pakistan asset value chart, confirms technological growth. The current indicator is 0.00. The financial model relies on the creation of lipid crystals, partnership agreements, and the funding of medical tests.

MTNB (matinasbiopharma.com) Company Short-Term Debts history from 07/04/2022 to 10/24/2026

MTNB (Matinas BioPharma Holdings, Inc.): analytical breakdowns and indicator data

- current quotes and average value forecast:
Price Chart Matinas BioPharma Holdings Inc.|MTNB - Fair Value Consensus
- market capitalization information:
Market Value Matinas BioPharma Holdings|MTNB - Real Price to Acquire Entire Company
- shareholders' equity book value data:
Book Value per Share Matinas BioPharma|MTNB - Book Capitalization|Market Cap to Net Assets Ratio matinasbiopharma.com|MTNB - Aggregate Asset Value
- debt and liquidity data:
Debt to Equity Matinas BioPharma|MTNB - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Matinas BioPharma Holdings Inc.|MTNB - Company Cumulative Debt|Debt to Book Value Matinas BioPharma Holdings|MTNB - Amount of Long-Term Liabilities|Company Short-Term Debts Matinas BioPharma|Quick Ratio matinasbiopharma.com
- net income and valuation multiples indicators:
MTNB - Company Net Income
Basic company analysis:matinasbiopharma.com - MTNB
Mass-produced product of Matinas BioPharma Holdings, Inc.

The dynamics of short-term liabilities reflect the business's liquidity vulnerability to external shocks, measuring the total debt maturing within one year to assess the issuer's solvency. The high potential of Matinas BioPharma (MTNB) LNC technology for oral drug delivery creates a foundation for capitalization; therefore, analyzing the level of short-term obligations allows investors to differentiate strategic R&D financing from a critical shortage of working capital.

Who Matinas BioPharma competes with

ASND - Company Short-Term Debt|Company Short-Term Loans and Borrowings MDGL (Madrigal Pharmaceuticals Inc)|Corcept (CORT) - Company Short-Term Debt|Company Current Liabilities Rhythm Corp|AKRO (Akero Therapeutics) - Company Short-Term Debts|Company Short-Term Debts metsera.com|Company Current Liabilities MLTX (MoonLake)|CRNX (Crinetics Pharmaceuticals, Inc.) - Company Short-Term Loans and Borrowings|Company Short-Term Debt NewAmsterdam Pharma N.V. NAMS|SLNO - Company Current Liabilities|Amicus Therapeutics - Company Short-Term Debts|Short-Term Debt 89bio.com|AGIO (Agios Pharmaceuticals, Inc.) - Company Current Liabilities|GPCR: Amount of Current Liabilities|MDXG (MiMedx Group) - Company Short-Term Debts|Company Short-Term Debts Rezolute Bio|Company Short-Term Debts LXRX|Company Short-Term Debt MBX (mbxbio.com)|Company Short-Term Debt Altimmune ALT|Aardvark Therapeutics Inc. (AARD) - Short-Term Debt|SGMT - Company Short-Term Debt|BIOA: Company Short-Term Debt|BMEA: Company Short-Term Debts|QNCX - Short-Term Debt Volume|Company Short-Term Debt Fractyl Health|vTv Therapeutics Inc (VTVT) - Short-Term Debt Volume|Company Short-Term Debt Agape ATP Corporation (ATPC)|Company Current Liabilities pluri-biotech.com PLUR|Company Short-Term Debt Synlogic SYBX|LPCN - Company Current Liabilities|Spruce Biosciences - Company Short-Term Debts|GLTO - Company Short-Term Debts|CTCX (Carmell Corp) - Company Current Liabilities|LUMO: Amount of Current Liabilities|ONVO (Organovo Holdings, Inc.) - Company Short-Term Debts|radiuspharm.com (RDUS) - Short-Term Debt Volume